跳至主要内容
临床试验/ACTRN12616000718448
ACTRN12616000718448暂停未知

A Feasibility Study to Assess Safety and Efficacy of the Transapical and Transfemoral JenaValve Pericardial TAVR (Transcatheter Aortic Valve Replacement) System in the Treatment of Patients with Symptomatic Severe Aortic Regurgitation (AR)

JenaValve Technology, Inc.0 个研究点目标入组 15 人开始时间: 2016年5月30日最近更新:
适应症

试验速览

阶段
未知
状态
暂停
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Patient with severe aortic regurgitation (AR) assessed by echocardiography
  • 2. Patient at high risk for open surgical valve replacement
  • 3. Patient symptomatic according to NYHA functional class II or higher.

排除标准

  • 1. Congenital uni- or bicuspid aortic valve morphology
  • 2. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  • 3. Endocarditis or other active infection
  • 4. Need for urgent or emergent TAVR procedure for any reason
  • 5. Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device

研究者

相似试验